Boston Scientific (BSX)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$47.80+1.81%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
Broken: Primary pillar broken — Cardiovascular segment grows at least 10% annually: Q2 FY26 total revenue +7.5% vs 10% target; Q3 FY26 guidance +3.0% to +5.0% vs 10% target.
Boston Scientific grows sales about 8% a year with strong cardiovascular gains. Profit margins stay near 13.5%. The company buys back stock and invests in new products. Recent earnings beats show execution despite challenges.
Product recalls and weaker outlook threaten sales growth. Guidance cuts and negative news create risks. Operational efficiency is mixed, pressuring profit margins and cash flow.
The price is about 44% below our fair value near $81. Analysts expect about 9% revenue growth. The market prices in risks from recent guidance cuts and product issues, which we partially agree with.
Breaks if: Cardiovascular segment growth falls below 7% next year
Breaks if: YoY revenue growth falls below 5% next year
No improvement in operational efficiency metrics over next year
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
BSX represents a durable compounder in the healthcare sector. The current thesis state is intact, supported by strong recent financial performance and ongoing management priorities focused on growth.
The market currently prices BSX as cheap compared to its peers, with a slight expectations gap suggesting that investors may not fully anticipate the company's potential for growth. The valuation reflects a medium level of confidence in its future performance.
Fundamentals are likely to continue reflecting strong growth, particularly in the cardiovascular segment, as management has consistently emphasized this priority. However, recent changes in company quality and elevated risks may pose challenges.
The thesis hinges on management's ability to maintain guidance and execute on growth initiatives. Additionally, broader sector performance and economic conditions, such as job reports, will influence BSX's trajectory.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company beat earnings expectations recently. This supports the view on net sales growth. However, management lowered guidance for WATCHMAN revenue. This indicates a decline in demand and competitive pressure.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Implement global restructuring programs to drive sustained cost efficiencies and support strategic priorities.
Breaks if: Operating margin falls below 12% next year
Over the next 1 to 3 years, BSX's performance will depend on its execution and external economic factors. Not investment advice.